Tristan Manalac is a Senior Staff Writer at BioSpace. Based in Metro Manila, Tristan has over eight years of experience covering a range of topics within medicine and healthcare, including pharmaceuticals, healthcare technology, and alternative medicine, with a keen interest in oncology, immunotherapy, and mental health care. He has been featured in BioSpace, where he shares his insights on the evolving landscape of medical specialties and innovative treatments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Tristan Manalac's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly FDA approvals, drug development, and related market movements. His reliance on press releases and data citations suggests a preference for fact-based reporting.
Given his focus on specific companies and regulatory developments in the pharmaceutical industry, Tristan is likely to be responsive to pitches from experts with direct knowledge of relevant drugs, therapies or regulatory processes. Additionally, he may be interested in insights into market trends impacting drug pricing or innovative approaches in drug development.
While geographic focus isn't specified, considering that pharma news often has global implications due to multinational companies involved in research and distribution of drugs worldwide would also be important when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Tristan Manalac
While Novartis' antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in secondary and exploratory measures.
By: Tristan Manalac
The approval opens up a “modest” market for AstraZeneca's Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significantly larger opportunity” for the drug.
As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.
By: Tristan Manalac
Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes.
Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, according to BMO Capital Markets.
By: Tristan Manalac
The decision to promote Michael Davis and Karim Mikhail from acting to permanent division heads comes as the FDA awaits the potential confirmation of Heidi Overton, President Donald Trump's nominee for commissioner.
By: Tristan Manalac
Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
Encoded Therapeutics' lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.
Frazier's life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for $2.7 billion.
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, which won the FDA’s approval last month for Mimrylo.
